Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
ABSTRACT #7508
Results of a Phase II clinical trial conducted at The University of Texas MD Anderson Cancer Center revealed that combination targeted therapy, consisting of rituximab, lenalidomide and ibrutinib (RLI), had an 84.6 percent overall response rate (ORR) and 38.5 percent complete response rate (CRR) when given prior to any chemotherapy for newly diagnosed patients with a specific type of diffuse large b-cell lymphoma...
Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
ABSTRACT 8504
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response...
Ribociclib plus hormone therapy extends survival for patients with premenopausal advanced hormone receptor-positive breast cancer
ABSTRACT LBA1008
Adding the targeted therapy ribociclib to hormone therapy significantly improved overall survival (OS) in premenopausal...
Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown to be effective when given together for high-risk and older patients with the disease, according to a study at The University of Texas MD Anderson Cancer Center.
Study findings were published in the May 29 online issue of the New England Journal of Medicine. Lead researchers included Nitin Jain, M.D., associate professor...
Texas raises tobacco sales age to 21 to limit youth exposure and protect health
The University of Texas MD Anderson Cancer Center applauds the Texas Legislature today for passing Senate Bill 21, which raises the minimum...
Polo on the Prairie raises $775,000 for cancer research, patient care
Despite a Saturday morning storm that wreaked havoc on plans for this year’s Polo on the Prairie, May 18 at the Musselman Brothers’ Lazy 3...
Ipilimumab and nivolumab immunotherapy combination produces high response rate in metastatic bladder cancer
An immunotherapy combination with a higher dose of ipilimumab produced a 38 percent overall response rate for patients with metastatic bladder...
MD Anderson applauds Texas Legislature for authorizing continuation of CPRIT to support cancer research, education and prevention
The University of Texas MD Anderson Cancer Center applauds the 86th Texas Legislature today for voting to approve a constitutional amendment...
MD Anderson leadership development program receives first-of-its-kind accreditation
The University of Texas MD Anderson Cancer Center has received full accreditation by the American Association for Physician Leadership...
Study shows MD Anderson-developed drug effective in overcoming ibrutinib resistance in mantle cell lymphoma
A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered...
2019 Andrew Sabin Family Fellows share passion for Making Cancer History
The University of Texas MD Anderson Cancer Center has named eight researchers to the fourth annual class of Andrew Sabin Family Fellows. Each...
New cancer therapy target found in mitochondria for potential treatment of blood cancers
A study at The University of Texas MD Anderson Cancer Center identified a new therapeutic target in cancer cells and explains how new anti-cancer...